Investing
Cathie Wood's ARK Invest Buys Over 530,000 Shares of Fate Therapeutics
Published:
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday. The fund bought over 530,000 shares of Fate Therapeutics Inc. (NASDAQ: FATE), as the price of this ETF was down over 2% on the day. Note that this fund is up significantly in the past year.
Specifically, ARK Innovation ETF (NYSEARCA: ARKK) bought 535,305 shares of Fate Therapeutics. At Wednesday’s closing price, this would have valued this purchase at roughly $46.2 million. Even though this is a small fraction of the total holdings, every little bit counts. The fund is up 60% in the past year.
Here’s a look at the other purchases across the ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | PATH | UiPath | 279,284 |
| ARKG | SGFY | Signify Health | 53,916 |
| ARKG | RXRX | Recursion Pharmaceuticals | 204,752 |
| ARKG | RPTX | Repare Therapeutics | 18,190 |
| ARKG | QSI | Quantum-Si | 359,389 |
| ARKG | MASS | 908 Devices | 47,945 |
| ARKK | FATE | Fate Therapeutics | 535,305 |
| ARKK | COIN | Coinbase Global | 20,165 |
| ARKK | TSLA | Tesla | 110,731 |
| ARKQ | PATH | UiPath | 135,228 |
| ARKW | VUZI | Vuzix | 521,151 |
| ARKW | FTCH | Farfetch | 599,955 |
| ARKX | AVAV | Aerovironment | 23,098 |
| ARKX | PATH | UiPath | 25,645 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
24/7 Wall St.Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
